Skip to main content

Research News

Crack GPAT — Prepare for GPAT Online 
  • Common mutation linked to COVID mortality

    it may be the most baffling quirk of COVID: What manifests as minor, flu-like symptoms in some individuals spirals into severe disease, disability, or even death in others. A new paper published in Nature may explain the genetic underpinnings of this dichotomy.

  • New study explains link between diabetes and UTIs

    Lower immunity and recurring infections are common in type 1 and type 2 diabetes. Researchers at Karolinska Institutet now show that the immune system of people with diabetes has lower levels of the antimicrobial peptide psoriasin, which compromises the urinary bladder’s cell barrier, increasing the risk of urinary tract infection. The study is published in Nature Communications.

  • How stressed tumor cells escape cell death: new mechanism discovered

    Because of their highly active metabolism, many tumors are susceptible to a special type of cell death, ferroptosis. Nevertheless, cancer cells often manage to escape this fate. Scientists at the German Cancer Research Center have now discovered a new mechanism by which normal as well as cancer cells protect themselves against ferroptosis. Knowledge of these molecular connections could provide new starting points for the treatment of tumors.

  • High performance artificial synaptic semiconductor device which mimics brain

    Neuromorphic computing system technology mimicking the human brain has emerged and overcome the limitation of excessive power consumption regarding the existing von Neumann computing method. A high-performance, analog artificial synapse device, capable of expressing various synapse connection strengths, is required to implement a semiconductor device that uses a brain information transmission method. This method uses signals transmitted between neurons when a neuron generates a spike signal.

  • Pfizer releases results from Phase 3 Study in pneumococcal conjugate vaccine

    Pfizer announced positive top-line results from its pivotal E.U. Phase 3 study in infants (NCT04546425) evaluating its 20-valent pneumococcal conjugate vaccine candidate (20vPnC) for the prevention of invasive pneumococcal disease (IPD), pneumonia, and acute otitis media caused by the 20 Streptococcus pneumoniae (pneumococcus) serotypes contained in the vaccine for the pediatric population.

  • New tool overcomes major hurdle in clinical AI design

    Harvard Medical School scientists and colleagues at Stanford University have developed an artificial intelligence diagnostic tool that can detect diseases on chest X-rays directly from natural-language descriptions contained in accompanying clinical reports.

  • Immunotherapy Reduces Lung and Liver Fibrosis in Mice

    Chronic diseases often lead to fibrosis, a condition in which organ tissue suffers from excessive scarring. Researchers at the University of Zurich have now developed an immunotherapy that specifically targets the cause – activated fibroblasts – while leaving normal connective tissue cells unharmed. If this approach is also found to work in humans, it could lead to an effective treatment for fibrosis.

  • Adult ADHD linked to elevated risk of cardiovascular diseases

    Adults with ADHD are at greater risk of developing a range of cardiovascular diseases than those without the condition, according to a large observational study led by researchers at Karolinska Institutet and Örebro University. The researchers say the findings, published in the journal World Psychiatry, underscore the need to monitor cardiovascular health in people with ADHD.

  • Pfizer Initiates Phase 3 Study of mRNA-Based Influenza Vaccine

    Pfizer Inc announced that the first participants have been dosed in a pivotal Phase 3 clinical trial to evaluate the efficacy, safety, tolerability and immunogenicity of the company’s quadrivalent modified RNA (modRNA) influenza vaccine candidate in approximately 25,000 healthy U.S. adults.

  • Drug Turns Cancer Gene Into Eat Me Flag for Immune System

    Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now, UC San Francisco researchers have developed a drug that overcomes some of these barriers, marking cancer cells for destruction by the immune system.

Subscribe to Research News